The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Hepatitis C Drug ANA598 Moves to Phase IIb

Back to News Homepage

Next

IP-10 Protein Levels Predict Hepatitis C Treatment Outcome

Update on Pharmasset's Hepatitis C Drug Candidates

January 11, 2011

Print this page

Pharmasset has released interim study results for several of its Hepatitis C drugs that are in different stages of testing.

Pharmasset Reports Interim Study Results For Its Hepatitis C Drugs

Thursday, January 06, 2011

Pharmasset (NASDAQ:VRUS) announced today interim results for the Phase 2b study for its PSI-7977 drug and the Phase 1 study for its PSI-938 drug. Both drugs are designed to treat Hepatitis C.

The Phase 2b study consisted of evaluating the effects of various PSI-7977 dosages in patients with Hepatitis C genotype 1, 2 or 3. The patients also received antiviral drugs commonly used to fight Hepatitis C.

Continue reading this entire article:
http://www.proactiveinvestors.com/companies/news/11228/pharmasset-reports-interim-study-results-for-its-hepatitis-c-drugs–11228.html

No Comments - be the first!
Share
Share

Previous

Hepatitis C Drug ANA598 Moves to Phase IIb

Back to News Homepage

Next

IP-10 Protein Levels Predict Hepatitis C Treatment Outcome

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.